1. Home
  2. HOTH vs INDP Comparison

HOTH vs INDP Comparison

Compare HOTH & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOTH
  • INDP
  • Stock Information
  • Founded
  • HOTH 2017
  • INDP 2000
  • Country
  • HOTH United States
  • INDP United States
  • Employees
  • HOTH N/A
  • INDP N/A
  • Industry
  • HOTH Biotechnology: Pharmaceutical Preparations
  • INDP Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOTH Health Care
  • INDP Health Care
  • Exchange
  • HOTH Nasdaq
  • INDP Nasdaq
  • Market Cap
  • HOTH 8.3M
  • INDP 8.8M
  • IPO Year
  • HOTH 2019
  • INDP N/A
  • Fundamental
  • Price
  • HOTH $1.06
  • INDP $0.80
  • Analyst Decision
  • HOTH Strong Buy
  • INDP Strong Buy
  • Analyst Count
  • HOTH 4
  • INDP 2
  • Target Price
  • HOTH $4.75
  • INDP $8.50
  • AVG Volume (30 Days)
  • HOTH 673.3K
  • INDP 28.5K
  • Earning Date
  • HOTH 03-27-2025
  • INDP 03-12-2025
  • Dividend Yield
  • HOTH N/A
  • INDP N/A
  • EPS Growth
  • HOTH N/A
  • INDP N/A
  • EPS
  • HOTH N/A
  • INDP N/A
  • Revenue
  • HOTH N/A
  • INDP N/A
  • Revenue This Year
  • HOTH N/A
  • INDP N/A
  • Revenue Next Year
  • HOTH N/A
  • INDP N/A
  • P/E Ratio
  • HOTH N/A
  • INDP N/A
  • Revenue Growth
  • HOTH N/A
  • INDP N/A
  • 52 Week Low
  • HOTH $0.58
  • INDP $0.72
  • 52 Week High
  • HOTH $3.80
  • INDP $3.10
  • Technical
  • Relative Strength Index (RSI)
  • HOTH 42.86
  • INDP 44.62
  • Support Level
  • HOTH $1.01
  • INDP $0.72
  • Resistance Level
  • HOTH $1.09
  • INDP $0.81
  • Average True Range (ATR)
  • HOTH 0.08
  • INDP 0.07
  • MACD
  • HOTH -0.02
  • INDP -0.00
  • Stochastic Oscillator
  • HOTH 25.93
  • INDP 34.43

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: